Damora's $533M Gambit: New Leadership and Novel Science Fuel Push into Rare Blood Cancers

BOSTON, MA – May 12, 2026 – Damora Therapeutics (NASDAQ: DMRA) today signaled an aggressive new chapter in its corporate story, outlining a rapid development strategy for its novel blood cancer therapies, backed by a formidable new leadership team and a war chest of over half a billion dollars. In its first quarterly report since a major corporate overhaul, the biotechnology company detailed ambitious timelines for its pipeline targeting mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs), a group of chronic blood cancers with significant unmet needs.

The announcement comes just months after a strategic transformation and the appointment of Jennifer Jarrett, a veteran biotech executive, as President and Chief Executive Officer. With approximately $533 million in cash, the company projects a financial runway extending into 2029, providing a stable foundation to execute its high-stakes plan to bring a potentially best-in-class treatment to market.

“We are pleased with our meaningful progress in advancing our mutant calreticulin (mutCALR)-targeted therapy pipeline,” Jarrett stated in the company's press release, emphasizing a clear strategy to challenge the current market leader and accelerate development.

A Biotech Reborn with a Powerhouse Team

Today’s Damora Therapeutics is fundamentally different from the company that traded on the Nasdaq just six months ago. The entity was formerly Galecto, Inc., which, in a strategic pivot, acquired the privately-held Damora Therapeutics and its promising anti-mutCALR portfolio in November 2025. The move was followed by a complete rebranding and a change in ticker symbol to DMRA in March 2026, marking a definitive shift in focus toward hematologic disorders.

This transformation was powered by a massive infusion of capital. The acquisition was supported by a concurrent $285 million private investment, which was quickly followed by a public offering in February 2026 that raised an additional $316 million. This financial fortification is now being deployed to rapidly advance its newly acquired assets.

Central to this revitalization is the assembly of a new leadership team with a deep history of success in oncology. CEO Jennifer Jarrett’s track record includes serving as Chief Financial Officer at Medivation, where she was instrumental in the commercial success of the blockbuster prostate cancer drug XTANDI® and the company’s eventual acquisition by Pfizer. Her more recent experience as COO at Arcus Biosciences further burnishes her credentials in building and scaling biotech firms.

Jarrett is joined by a team of seasoned executives, many hailing from Blueprint Medicines, another oncology success story. This includes Chief Operating Officer Sherwin Sattarzadeh and Chief Medical Officer Dr. Becker Hewes. The board has also been strengthened with industry heavyweights, signaling to investors that the company is built for execution and long-term growth.

Targeting the Engine of a Difficult Disease

Damora is focusing on a specific genetic driver of MPNs: mutations in the calreticulin gene. These mutations are found in a significant portion of patients with essential thrombocythemia (ET) and myelofibrosis (MF), two chronic blood cancers. In ET, the body produces too many platelets, increasing the risk of life-threatening blood clots, while MF involves the scarring of bone marrow, leading to severe anemia and an enlarged spleen. For the estimated 42,000 patients in the U.S. with mutCALR-driven MPNs, current treatments manage symptoms but do not target the underlying cause of the disease.

Damora aims to change this with a sophisticated, multi-pronged antibody platform designed to attack the cancer at its source:

• DMR-001: The lead candidate is an Fc-null antibody designed to block the cancer-causing signals from mutCALR without engaging the broader immune system. Preclinical research, set to be presented at the upcoming European Hematology Association (EHA) Congress, has reportedly shown it to be approximately 10 times more potent against certain mutCALR mutations than a reference molecule already in clinical development. Its extended half-life also suggests the potential for a convenient subcutaneous injection for patients.

• DMR-002: This Fc-enhanced antibody is engineered to amplify the immune system’s natural ability to find and kill malignant cells through a process called antibody-dependent cellular cytotoxicity.

• DMR-003: A bi-specific T-cell engager, this antibody is designed to act as a bridge, recruiting the body's powerful T-cells to directly target and eliminate the cancerous cells.

This portfolio approach, leveraging three distinct mechanisms, uniquely positions the company to potentially treat a wide spectrum of patients, regardless of their specific mutation type or disease severity.

An Aggressive Race to the Clinic and Market

With its team and financing in place, Damora is not wasting time. The company has laid out an aggressive timeline that aims to rapidly translate its preclinical promise into clinical data. The first regulatory submission to enable a global Phase 1/1b trial for its lead asset, DMR-001, is slated for mid-2026. The trial itself is designed for speed, using an adaptive Bayesian design to quickly identify the right dose and begin generating data in both ET and MF patients by mid-2027.

If successful, this rapid progression could see the initiation of a pivotal Phase 3 study as early as mid-2028. The company's strategy explicitly acknowledges a competitive landscape, with Jarrett noting the goal is to “maintain or reduce the time to market entry following the current mutCALR leader.”

This accelerated plan is reflected in the company's financials. Research and development expenses soared to $23.8 million in the first quarter of 2026, a dramatic increase from just $0.7 million in the same period last year. Similarly, general and administrative costs rose to $7.0 million from $1.9 million. While this led to a net loss of $27.8 million for the quarter, the spending is a direct and necessary consequence of scaling up manufacturing, preclinical studies, and the corporate infrastructure required to drive its ambitious clinical programs forward.